药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Gancotamab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Gancotamab.
Mecasermin
Setrusumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Setrusumab.
Mecasermin
Camrelizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Camrelizumab.
Mecasermin
Cemiplimab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Cemiplimab.
Mecasermin
Lanadelumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lanadelumab.
Mecasermin
Lecanemab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lecanemab.
Mecasermin
Fanolesomab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fanolesomab.
Mecasermin
Galcanezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Galcanezumab.
Mecasermin
Fremanezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fremanezumab.
Mecasermin
Eptinezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eptinezumab.
Mecasermin
Erenumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Erenumab.
Mecasermin
Burosumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Burosumab.
Mecasermin
Besilesomab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Besilesomab.
Mecasermin
Sulesomab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sulesomab.
Mecasermin
Emicizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Emicizumab.
Mecasermin
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Human cytomegalovirus immune globulin.
Mecasermin
Nebacumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Nebacumab.
Mecasermin
Edrecolomab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Edrecolomab.
Mecasermin
Bezlotoxumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bezlotoxumab.
Mecasermin
Olokizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Olokizumab.